In recent years, cancer immunotherapy has revolutionized the field of oncology and is evolving as an effective and less invasive strategy that can be applied to the treatment of various malignancies. Among the targeted cancer immunotherapies, checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy have shown impressive response rates and signify an unprecedented success in cancer immunotherapy, particularly in patients failing all other therapies. CAR T cell therapy is a cellular therapy that redirects a patient’s T cells to specifically target and destroy tumor cells. CARs are genetically engineered fusion proteins consisting of an antigen recognition domain derived from a monoclonal antibody, along with intracellular T cell signaling and costimulatory domains.

Among viral vectors, lentiviral vectors (LVs) have demonstrated exceptional promise as tools for gene therapy due to their efficient gene integration and stable expression of the gene of interest in target cells. Given that integration patterns of LVs have a significantly lower risk of random transgene integration and oncogenic transformation compared to other viral vectors, producing a safe and efficient CAR T-cell product using this delivery vehicle is feasible. LVs also present lower manufacturing costs than other viral and nonviral gene delivery approaches and can efficiently transduce not only dividing but also non-dividing cells. This capability allows for the targeting of a wide variety of cells, including hard-to-transduce cells such as hematopoietic precursors, neurons, lymphoid cells, and macrophages.

Our CAR Lentiviral Services
As a leader in lentiviral technology, the QVirus™ Platform provides well-validated and widely used products and services for lentivirus production, which deliver ultra-high titer virus for dependable T-cell transduction. Systematic optimization has been carried out to increase the ability of lentivirus to carry exogenous genes, enhance the affinity of lentivirus to cells from different tissue sources, and maximize lentivirus production and titer. The lentivirus constructed by our platform is proven via FACS to efficiently infect T cells, with the capability of large-scale production (1-10 mL of ultra-high titer virus) available.

Workflows

Transfection into packaging cells
Virus collection, concentration, and titer determination
Lentiviral transduction and CAR-T expansion
Measurements of CAR expression, INF-γ & IL-2 induction, and cytotoxicity
Features
High titer lentivirus production
Serum-free virus preparation system
Suitable for in vivo applications
Clinical and R&D-grade CAR-T virus packaging services
The QVirus™ Platform offers a one-stop service for ultra-high titer lentivirus production for CAR-T cell therapies.